News Headlines Article

Gilead to sell pricey hepatitis C drug in poor countries for fraction of U.S. cost
San Francisco Business Times

Gilead Sciences Inc. will make its pricey hepatitis C drug Sovaldi available in about 80 poorer countries for less than the cost of a single pill in the United States, according to Bloomberg.

Gilead executive vice president Gregg Alton told the news agency that a broad licensing deal with a handful of generic drug makers could be completed by mid-September. After winning regulatory approvals in those countries, Sovaldi then could be sold in India, Indonesia, Pakistan and the other countries for $900 for 12 weeks of therapy.